Laurus Labs Analyst Review May 2026

This Laurus Labs analyst review for May 2026 covers the key data investors need for LAURUSLABS at its current price of Rs 1,325.00. Laurus Labs (NSE: LAURUSLABS) is a leading pharma company specialising in APIs, generic formulations, and CDMO services with a market capitalisation of approximately Rs 61,300 crore. The analyst consensus target of Rs 1,650 implies meaningful upside, and this Laurus Labs analyst review examines technical levels, business performance, valuation, and key risks that will determine whether LAURUSLABS achieves that target through FY27.

Click Here – Get Free Investment Predictions

Laurus Labs Company Snapshot May 2026

Laurus’s ARV API dominance for sub-Saharan Africa markets, US oral solid dosage formulations via Laurus Generics, and the CDMO synthesis business for global innovator clients are the three distinct high-quality growth pillars. The table below summarises the key data referenced in this Laurus Labs analyst review.

Parameter	Value
NSE Ticker	LAURUSLABS
Sector	Pharmaceuticals – APIs and CDMO
CMP (May 2026)	Rs 1,325.00
52 Week High	Rs 1,327.90
52 Week Low	Rs 584.50
Market Cap	Rs 61,300 Crore
Trailing P/E	65x
Analyst Consensus Target	Rs 1,650
Bull Case Target	Rs 2,100
Bear Case Target	Rs 1,050

Analyst Insight in This Laurus Labs Analyst Review

Associate Director Kunal Singla suggests watching Laurus Labs closely in May 2026. At Rs 1,325.00, Kunal Singla flags Pharmaceuticals – APIs and CDMO sector dynamics as the primary driver for LAURUSLABS’s near-term price action. He notes support in the Rs 596 to Rs 1259 zone and flags any sustained close above Rs 1404 as a positive signal worth tracking. Kunal Singla’s perspective on Laurus Labs adds professional analysis to this Laurus Labs analyst review and is not a buy recommendation.

Technical Analysis in This Laurus Labs Analyst Review

At Rs 1,325.00, LAURUSLABS is trading within its 52-week band of Rs 584.50 to Rs 1,327.90. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 596 to Rs 1259 band while resistance is seen in the Rs 1404 to Rs 1488 zone. A sustained move above Rs 1404 could open the path toward the analyst consensus target of Rs 1,650.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 596 to Rs 1259 – investors tracking this Laurus Labs analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for LAURUSLABS.
• Resistance Zone: Rs 1404 to Rs 1488 – a sustained close above Rs 1404 would be a positive breakout signal worth flagging in this Laurus Labs analyst review.
• Medium-Term Target: The analyst consensus of Rs 1,650 represents the base-case upside scenario identified in this Laurus Labs analyst review.

Business Segment Analysis

APIs (ARV and Non-ARV – Large Scale Manufacturing)

This is the primary revenue and margin driver for Laurus Labs, directly supporting the earnings trajectory toward the consensus target of Rs 1,650.

Generic Formulations (US Oral Solid Dosage)

This segment adds scale and diversification to Laurus Labs’s business model and is a meaningful EPS contributor through FY27 and FY28.

CDMO Synthesis for Global Pharma Innovators

This represents the medium-term growth frontier for Laurus Labs and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Laurus Labs Analyst Review

At Rs 1,325.00, Laurus Labs trades at a trailing P/E of 65x. This Laurus Labs analyst review presents three valuation scenarios: a bull case of Rs 2,100 on strong earnings delivery and sector tailwinds, a base case of Rs 1,650 at analyst consensus, and a bear case of Rs 1,050 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Laurus Labs analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 2,100	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 1,650	Moderate growth, analyst consensus estimate
Bear Case	Rs 1,050	Earnings miss or macro headwinds

Trade Outlook for Laurus Labs

Based on the technical and fundamental analysis in this Laurus Labs analyst review, investors might watch LAURUSLABS near the support zone of Rs 596 to Rs 1259 for potential opportunities. A flag above Rs 1404 could suggest improving momentum toward Rs 1,650. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Laurus Labs in FY27

A well-rounded Laurus Labs analyst review must assess downside risks. Key risks for Laurus Labs include a macro slowdown affecting Pharmaceuticals – APIs and CDMO sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in LAURUSLABS.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Laurus Labs Analyst Review Verdict for 2026

This Laurus Labs analyst review concludes that at Rs 1,325.00, LAURUSLABS offers a defined risk-reward with a consensus target of Rs 1,650. The 52-week range of Rs 584.50 to Rs 1,327.90 provides context on the current entry point. Use this Laurus Labs analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on LAURUSLABS.

Frequently Asked Questions: Laurus Labs Analyst Review 2026

What is the analyst target for Laurus Labs in 2026?

The analyst consensus target is Rs 1,650, with a bull case of Rs 2,100 and a bear case of Rs 1,050. Monitor Q1 FY27 earnings for confirmation as highlighted in this Laurus Labs analyst review.

Is Laurus Labs a good investment at Rs 1,325.00?

At Rs 1,325.00 with a P/E of 65x and a consensus target of Rs 1,650, this Laurus Labs analyst review is constructive for medium to long-term investors in the Pharmaceuticals – APIs and CDMO sector. Always consult a SEBI-registered advisor before investing.

What is Laurus Labs’s 52-week high and low?

The 52-week high is Rs 1,327.90 and the 52-week low is Rs 584.50. At Rs 1,325.00, LAURUSLABS is positioned within this range as noted in this Laurus Labs analyst review.

What are the key risks for Laurus Labs?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – APIs and CDMO sector as assessed in this Laurus Labs analyst review.

Where can I track live data for Laurus Labs?

Track Laurus Labs’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Laurus Labs analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.